(Q33913549)

30 July 2017

title

Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer (English)

1 reference

30 July 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

Dana B Cardin

1

1 reference

30 July 2017

Laura Goff

2

1 reference

30 July 2017

Chung-I Li

3

1 reference

30 July 2017

Yu Shyr

4

1 reference

30 July 2017

Charles Winkler

5

1 reference

30 July 2017

Russell DeVore

6

1 reference

30 July 2017

Larry Schlabach

7

1 reference

30 July 2017

Melanie Holloway

8

1 reference

30 July 2017

Pam McClanahan

9

1 reference

30 July 2017

Krista Meyer

10

1 reference

30 July 2017

Julia Grigorieva

11

1 reference

30 July 2017

Jordan Berlin

12

1 reference

30 July 2017

Emily Chan

13

1 reference

30 July 2017

language of work or name

English

0 references

publication date

12 February 2014

1 reference

30 July 2017

1 reference

30 July 2017

volume

3

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

572-579

1 reference

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCAM4.208

A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCAM4.208

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4101748

Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24574334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24574334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24574334

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/CAM4.208

1 reference

30 July 2017

1 reference

30 July 2017

1 reference